Category: Sofosbuvir
The HepC Pill Bill
Source : hepCoalition The HepC Pill Bill-An insight into the availability, pricing and accessibility of HCV treatment Introduction to Direct Acting Antivirals Hepatitis C treatment has remarkably evolved over the years. The previously known standard HCV regimen consisted of a...
Amendment of the TRIPS Agreement
WTO members on 6 December 2005 approved changes to the WTO’s intellectual property (TRIPS) agreement in order to make permanent a decision on patents and public health originally adopted in 2003. This was formally built into the TRIPS Agreement after...
Launch of Moroccan Generic Sofosbuvir: A Victory for the Wide-spread Use HCV Treatment in Morocco
According to the Ministry of Health, 625,000 people are infected by HCV, 1.6% of the general population of Morocco. Of those infected, 267,000 people have active chronic infection requiring treatment. Until recently, the management of HCV infection has been hampered...
Treatment Advocates Denounce Gilead’s Embargo against Thousands of Tunisians Suffering from HCV Infection
The Tunisian Association of Fight against STDs and AIDS (ATL Tunis) and the International Treatment Preparedness Coalition in MENA Region (ITPC-MENA) denounce the refusal of Gilead Sciences to make their drug against the Hepatitis C Virus (HCV), sofosbuvir, available to...